Evogene (NASDAQ: EVGN) reported Q1 EPS of ($0.38), $0.35 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $2.44 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.